SAVA vs. TYRA, IMNM, OCUL, ABVX, SPRY, CNTA, ARQT, LQDA, INVA, and OPK
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Tyra Biosciences (TYRA), Immunome (IMNM), Ocular Therapeutix (OCUL), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), Centessa Pharmaceuticals (CNTA), Arcutis Biotherapeutics (ARQT), Liquidia (LQDA), Innoviva (INVA), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Cassava Sciences (NASDAQ:SAVA) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.
In the previous week, Cassava Sciences had 2 more articles in the media than Tyra Biosciences. MarketBeat recorded 3 mentions for Cassava Sciences and 1 mentions for Tyra Biosciences. Cassava Sciences' average media sentiment score of 0.34 beat Tyra Biosciences' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.
Cassava Sciences received 79 more outperform votes than Tyra Biosciences when rated by MarketBeat users. Likewise, 66.20% of users gave Cassava Sciences an outperform vote while only 57.69% of users gave Tyra Biosciences an outperform vote.
38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 12.2% of Cassava Sciences shares are held by insiders. Comparatively, 15.4% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Cassava Sciences has a beta of -0.38, indicating that its share price is 138% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
Cassava Sciences currently has a consensus price target of $124.00, indicating a potential upside of 474.87%. Tyra Biosciences has a consensus price target of $22.00, indicating a potential upside of 22.02%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Tyra Biosciences.
Tyra Biosciences is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.
Tyra Biosciences' return on equity of -30.26% beat Cassava Sciences' return on equity.
Summary
Tyra Biosciences beats Cassava Sciences on 8 of the 15 factors compared between the two stocks.
Get Cassava Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cassava Sciences Competitors List
Related Companies and Tools
